We are live on
!
Find out more
Alkeon Capital Management Portfolio holdings
AUM
$59.5B
1-Year Est. Return
51.63%
This Fund
S&P 500
This Quarter
Est. Return
+14.24%
1 Year Est. Return
+51.63%
3 Year Est. Return
+162.63%
5 Year Est. Return
+168.42%
10 Year Est. Return
+1,374.92%
AUM
$68B
AUM Growth
+$7.99B
(+13%)
Cap. Flow
+$1.7B
Cap. Flow
% of AUM
2.5%
Top 10 Holdings %
Top 10 Hldgs %
64.5%
Holding
118
New
15
Increased
22
Reduced
27
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$185M |
| 2 |
BWX Technologies
BWXT
|
+$157M |
| 3 |
Amphenol
APH
|
+$157M |
| 4 |
Microsoft
MSFT
|
+$128M |
| 5 |
Teradyne
TER
|
+$103M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$593M |
| 2 |
KLA
KLAC
|
+$252M |
| 3 |
Lam Research
LRCX
|
+$221M |
| 4 |
Alibaba
BABA
|
+$184M |
| 5 |
Dell
DELL
|
+$130M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.71% |
| 2 | Consumer Discretionary | 5.14% |
| 3 | Communication Services | 4.3% |
| 4 | Financials | 2.62% |
| 5 | Industrials | 2.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Keros Therapeutics
KROS
$214M
| $13.5M | 0.02% |
850,511
| – | – |
|
102
dLocal
DLO
$4.22B
| $11.8M | 0.02% |
823,837
| – | – |
|
|
MREO
103
Mereo BioPharma
MREO
$45.5M
| $7.62M | 0.01% |
3,698,100
-1,000,000
| -21% | -$1.84M |
|
104
Paylocity
PCTY
$7.89B
| $3.93M | 0.01% |
24,683
| – | – |
|
105
Alto Neuroscience
ANRO
$1.08B
| $1.92M | ﹤0.01% |
477,101
| – | – |
|
106
Applied Materials
AMAT
$420B
| – | – |
-45,000
| Closed | -$8.24M |
|
107
ASML
ASML
$671B
| – | – |
-6,500
| Closed | -$5.21M |
|
|
108
Alibaba
BABA
$315B
| – | – |
-1,625,000
| Closed | -$184M |
|
|
109
PUT
Alphabet (Google) Class A
GOOGL
$4.33T
| – | – |
-230,000
| Closed | -$40.5M |
|
110
Okta
OKTA
$26.5B
| – | – |
-380,000
| Closed | -$38M |
|
111
CALL
Oracle
ORCL
$431B
| – | – |
-4,000,000
| Closed | -$875M |
|
|
112
PUT
Oracle
ORCL
$431B
| – | – |
-220,000
| Closed | -$48.1M |
|
113
PMV Pharmaceuticals
PMVP
$62.9M
| – | – |
-2,342,373
| Closed | -$2.48M |
|
114
Ultragenyx Pharmaceutical
RARE
$2.58B
| – | – |
-1,685,729
| Closed | -$61.3M |
|
115
Sony
SONY
$140B
| – | – |
-275,000
| Closed | -$7.16M |
|
116
PUT
TSMC
TSM
$2.18T
| – | – |
-300,000
| Closed | -$67.9M |
|
Similar funds
QCM
NAMI
Alkeon Capital Management's Q3 2025 Portfolio in Review
As of Q3 2025, Alkeon Capital Management held 118 positions worth $68B, up 13% from $60B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Alkeon Capital Management's Q3 2025 filing shows 15 new, 22 increased, 27 reduced and 12 closed positions. Its largest new stake was CRH: 1,750,000 shares worth $210M. The largest sale was Alphabet (Google) Class A, an estimated $593M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Alkeon Capital Management's largest Q3 2025 buy was CRH: 1,750,000 shares worth $210M.
- Alkeon Capital Management added most to BWX Technologies in Q3 2025, an estimated $157M increase.
- Alkeon Capital Management's biggest Q3 2025 reduction was Alphabet (Google) Class A, cutting an estimated $593M.
- Alkeon Capital Management fully exited Alibaba in Q3 2025, selling an estimated $184M.
- Alkeon Capital Management's ten largest holdings make up 65% of its $68B portfolio in Q3 2025.
- Alkeon Capital Management opened 15 new positions and closed 12 in Q3 2025.
- Alkeon Capital Management's portfolio value rose 13% quarter-over-quarter to $68B.
Based on Alkeon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.